Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Therapeutic Applications of Curcumin and its Novel Formulations in the Treatment of Bladder Cancer: A Review of Current Evidence

Author(s): Mohammad H. Pourhanifeh, Reza Mottaghi, Zahra S. Razavi, Alimohammad Shafiee, Sarah Hajighadimi and Hamed Mirzaei*

Volume 21, Issue 5, 2021

Published on: 07 August, 2020

Page: [587 - 596] Pages: 10

DOI: 10.2174/1871520620666200807223832

Price: $65

Abstract

Bladder cancer, a life-threatening serious disease, is responsible for thousands of cancer-associated deaths worldwide. Similar to other malignancies, standard treatments of bladder cancer, such as Chemoradiotherapy, are not efficient enough in the affected patients. It means that, according to recent reports in the case of life quality as well as the survival time of bladder cancer patients, there is a critical requirement for exploring effective treatments. Recently, numerous investigations have been carried out to search for appropriate complementary treatments or adjuvants for bladder cancer therapy. Curcumin, a phenolic component with a wide spectrum of biological activities, has recently been introduced as a potential anti-cancer agent. It has been shown that this agent exerts its therapeutic effects via targeting a wide range of cellular and molecular pathways involved in bladder cancer. Herein, the current data on curcumin therapy for bladder cancer are summarized.

Keywords: Bladder cancer, curcumin, natural compound, inflammation, autophagy, angiogenesis, analog, delivery system, apoptosis, oxidativestress, cancer therapy, urology.`

« Previous Next »
Graphical Abstract

[1]
Luqmani, Y.A. Mechanisms of drug resistance in cancer chemotherapy, Medical principles and practice: International journal of the Kuwait University. Health Sci. Centre, 2005, 14(Suppl. 1), 35-48.
[2]
Böhle, A.; Jurczok, A.; Ardelt, P.; Wulf, T.; Ulmer, A.J.; Jocham, D.; Brandau, S. Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo. J. Urol., 2002, 167(1), 357-363.
[http://dx.doi.org/10.1016/S0022-5347(05)65468-7] [PMID: 11743356]
[3]
Sylvester, R.J.; Oosterlinck, W.; Holmang, S.; Sydes, M.R.; Birtle, A.; Gudjonsson, S.; De Nunzio, C.; Okamura, K.; Kaasinen, E.; Solsona, E.; Ali-El-Dein, B.; Tatar, C.A.; Inman, B.A.; N’Dow, J.; Oddens, J.R.; Babjuk, M. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: Which patients benefit from the instillation? Eur. Urol., 2016, 69(2), 231-244.
[http://dx.doi.org/10.1016/j.eururo.2015.05.050] [PMID: 26091833]
[4]
Perlis, N.; Zlotta, A.R.; Beyene, J.; Finelli, A.; Fleshner, N.E.; Kulkarni, G.S. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: An updated meta-analysis on 2548 patients and quality-of-evidence review. Eur. Urol., 2013, 64(3), 421-430.
[http://dx.doi.org/10.1016/j.eururo.2013.06.009] [PMID: 23830475]
[5]
Nguyen, D.P.; Thalmann, G.N. Contemporary update on neoadjuvant therapy for bladder cancer. Nat. Rev. Urol., 2017, 14(6), 348-358.
[http://dx.doi.org/10.1038/nrurol.2017.30] [PMID: 28290459]
[6]
Allegra, A.; Innao, V.; Russo, S.; Gerace, D.; Alonci, A.; Musolino, C. Anticancer activity of curcumin and its analogues: Preclinical and clinical studies. Cancer Invest., 2017, 35(1), 1-22.
[http://dx.doi.org/10.1080/07357907.2016.1247166] [PMID: 27996308]
[7]
Hesari, A.; Azizian, M.; Sheikhi, A.; Nesaei, A.; Sanaei, S.; Mahinparvar, N.; Derakhshani, M.; Hedayt, P.; Ghasemi, F.; Mirzaei, H. Chemopreventive and therapeutic potential of curcumin in esophageal cancer: Current and future status. Int. J. Cancer, 2019, 144(6), 1215-1226.
[8]
Kunnumakkara, A.B.; Anand, P.; Aggarwal, B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett., 2008, 269(2), 199-225.
[http://dx.doi.org/10.1016/j.canlet.2008.03.009] [PMID: 18479807]
[9]
Aggarwal, B.B.; Harikumar, K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol., 2009, 41(1), 40-59.
[http://dx.doi.org/10.1016/j.biocel.2008.06.010] [PMID: 18662800]
[10]
Ghasemi, F.; Shafiee, M.; Banikazemi, Z.; Pourhanifeh, M.H.; Khanbabaei, H.; Shamshirian, A.; Amiri Moghadam, S. ArefNezhad, R.; Sahebkar, A.; Avan, A.; Mirzaei, H. Curcumin inhibits NF-kB and Wnt/β-catenin pathways in cervical cancer cells. Pathol. Res. Pract., 2019, 215(10)152556
[http://dx.doi.org/10.1016/j.prp.2019.152556] [PMID: 31358480]
[11]
Shafabakhsh, R.; Pourhanifeh, M.H.; Mirzaei, H.R.; Sahebkar, A.; Asemi, Z.; Mirzaei, H. Targeting regulatory T cells by curcumin: A potential for cancer immunotherapy. Pharmacol. Res., 2019, 147104353
[http://dx.doi.org/10.1016/j.phrs.2019.104353] [PMID: 31306775]
[12]
Watanabe, F.T.; Chade, D.C.; Reis, S.T.; Piantino, C. Dall’ Oglio, M.F.; Srougi, M.; Leite, K.R. Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic murine orthotopic bladder tumor model. Clinics (São Paulo), 2011, 66(12), 2121-2124.
[http://dx.doi.org/10.1590/S1807-59322011001200019] [PMID: 22189739]
[13]
Kamat, A.M.; Tharakan, S.T.; Sung, B.; Aggarwal, B.B. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res., 2009, 69(23), 8958-8966.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-2045] [PMID: 19903839]
[14]
Park, B.H.; Lim, J.E.; Jeon, H.G.; Seo, S.I.; Lee, H.M.; Choi, H.Y.; Jeon, S.S.; Jeong, B.C. Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2. Oncotarget, 2016, 7(39), 63870-63886.
[http://dx.doi.org/10.18632/oncotarget.11563] [PMID: 27564099]
[15]
Hauser, P.J.; Han, Z.; Sindhwani, P.; Hurst, R.E. Sensitivity of bladder cancer cells to curcumin and its derivatives depends on the extracellular matrix. Anticancer Res., 2007, 27(2), 737-740.
[PMID: 17465196]
[16]
Kumar, V.; Abbas, A.K.; Fausto, N.; Aster, J.C. Robbins and Cotran pathologic basis of disease, professional edition e-book; Elsevier Health Sciences: UK, 2014.
[17]
Christensen, C.H.; Rostron, B.; Cosgrove, C.; Altekruse, S.F.; Hartman, A.M.; Gibson, J.T.; Apelberg, B.; Inoue-Choi, M.; Freedman, N.D. Association of cigarette, cigar, and pipe use with mortality risk in the US population. JAMA Intern. Med., 2018, 178(4), 469-476.
[http://dx.doi.org/10.1001/jamainternmed.2017.8625] [PMID: 29459935]
[18]
Alfred Witjes, J.; Lebret, T.; Compérat, E.M.; Cowan, N.C.; De Santis, M.; Bruins, H.M.; Hernández, V.; Espinós, E.L.; Dunn, J.; Rouanne, M.; Neuzillet, Y.; Veskimäe, E.; van der Heijden, A.G.; Gakis, G.; Ribal, M.J. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol., 2017, 71(3), 462-475.
[http://dx.doi.org/10.1016/j.eururo.2016.06.020] [PMID: 27375033]
[19]
Bellmunt, J.; Orsola, A.; Leow, J.J.; Wiegel, T.; De Santis, M.; Horwich, A. ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2014, 25(Suppl. 3), iii40-iii48.
[http://dx.doi.org/10.1093/annonc/mdu223] [PMID: 25096609]
[20]
Babjuk, M.; Böhle, A.; Burger, M.; Capoun, O.; Cohen, D.; Compérat, E.M.; Hernández, V.; Kaasinen, E.; Palou, J.; Rouprêt, M.; van Rhijn, B.W.; Shariat, S.F.; Soukup, V.; Sylvester, R.J.; Zigeuner, R. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur. Urol., 2017, 71(3), 447-461.
[http://dx.doi.org/10.1016/j.eururo.2016.05.041] [PMID: 27324428]
[21]
Sonpavde, G.; Goldman, B.H.; Speights, V.O.; Lerner, S.P.; Wood, D.P.; Vogelzang, N.J.; Trump, D.L.; Natale, R.B.; Grossman, H.B.; Crawford, E.D. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer, 2009, 115(18), 4104-4109.
[http://dx.doi.org/10.1002/cncr.24466] [PMID: 19517476]
[22]
Bosschieter, J.; Nieuwenhuijzen, J.A.; van Ginkel, T.; Vis, A.N.; Witte, B.; Newling, D.; Beckers, G.M.A.; van Moorselaar, R.J.A. Value of an immediate intravesical instillation of Mitomycin C in patients with non-muscle-invasive bladder cancer: A prospective multicentre randomised study in 2243 patients. Eur. Urol., 2018, 73(2), 226-232.
[http://dx.doi.org/10.1016/j.eururo.2017.06.038] [PMID: 28705539]
[23]
Messing, E.M.; Tangen, C.M.; Lerner, S.P.; Sahasrabudhe, D.M.; Koppie, T.M.; Wood, D.P., Jr; Mack, P.C.; Svatek, R.S.; Evans, C.P.; Hafez, K.S.; Culkin, D.J.; Brand, T.C.; Karsh, L.I.; Holzbeierlein, J.M.; Wilson, S.S.; Wu, G.; Plets, M.; Vogelzang, N.J.; Thompson, I.M., Jr Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA, 2018, 319(18), 1880-1888.
[http://dx.doi.org/10.1001/jama.2018.4657] [PMID: 29801011]
[24]
Jones, G.; Cleves, A.; Wilt, T.J.; Mason, M.; Kynaston, H.G.; Shelley, M. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst. Rev., 2012, 1CD009294
[http://dx.doi.org/10.1002/14651858.CD009294.pub2] [PMID: 22259002]
[25]
Shelley, M.D.; Wilt, T.J.; Court, J.; Coles, B.; Kynaston, H.; Mason, M.D. Intravesical Bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: A meta-analysis of randomized trials. BJU Int., 2004, 93(4), 485-490.
[http://dx.doi.org/10.1111/j.1464-410X.2003.04655.x] [PMID: 15008714]
[26]
Böhle, A.; Jocham, D.; Bock, P.R. Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol., 2003, 169(1), 90-95.
[http://dx.doi.org/10.1016/S0022-5347(05)64043-8] [PMID: 12478111]
[27]
Mirzaei, H.; Shakeri, A.; Rashidi, B.; Jalili, A.; Banikazemi, Z.; Sahebkar, A. Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies. Biomed. Pharmacother., 2017, 85, 102-112.
[28]
Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: Problems and promises. Mol. Pharm., 2007, 4(6), 807-818.
[http://dx.doi.org/10.1021/mp700113r] [PMID: 17999464]
[29]
Ireson, C.; Orr, S.; Jones, D.J.; Verschoyle, R.; Lim, C.K.; Luo, J.L.; Howells, L.; Plummer, S.; Jukes, R.; Williams, M.; Steward, W.P.; Gescher, A. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res., 2001, 61(3), 1058-1064.
[PMID: 11221833]
[30]
Pan, M.H.; Huang, T.M.; Lin, J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos., 1999, 27(4), 486-494.
[PMID: 10101144]
[31]
Wahlström, B.; Blennow, G. A study on the fate of curcumin in the rat. Acta Pharmacol. Toxicol. (Copenh.), 1978, 43(2), 86-92.
[http://dx.doi.org/10.1111/j.1600-0773.1978.tb02240.x] [PMID: 696348]
[32]
Sharma, R.A.; Steward, W.P.; Gescher, A.J. Pharmacokinetics and pharmacodynamics of curcumin. InThe Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease; Springer: New York, 2007, pp. 453-470.
[http://dx.doi.org/10.1007/978-0-387-46401-5_20]
[33]
Ravindranath, V.; Chandrasekhara, N. Absorption and tissue distribution of curcumin in rats. Toxicology, 1980, 16(3), 259-265.
[http://dx.doi.org/10.1016/0300-483X(80)90122-5] [PMID: 7423534]
[34]
Ravindranath, V.; Chandrasekhara, N. In vitro studies on the intestinal absorption of curcumin in rats. Toxicology, 1981, 20(2-3), 251-257.
[http://dx.doi.org/10.1016/0300-483X(81)90056-1] [PMID: 7256789]
[35]
Gutierres, V.O.; Campos, M.L.; Arcaro, C.A.; Assis, R.P.; Baldan-Cimatti, H.M.; Peccinini, R.G.; Paula-Gomes, S.; Kettelhut, I.C.; Baviera, A.M.; Brunetti, I.L. Curcumin pharmacokinetic and pharmacodynamic evidences in streptozotocin-diabetic rats support the antidiabetic activity to be via metabolite(s). Evid. Based Complement. Alternat. Med., 2015, 2015678218
[36]
Küllenberg, D.; Taylor, L.A.; Schneider, M.; Massing, U. Health effects of dietary phospholipids. Lipids Health Dis., 2012, 11, 3.
[http://dx.doi.org/10.1186/1476-511X-11-3] [PMID: 22221489]
[37]
Grattagliano, I.; Diogo, C.V.; Mastrodonato, M.; de Bari, O.; Persichella, M.; Wang, D.Q.; Liquori, A.; Ferri, D.; Carratù, M.R.; Oliveira, P.J.; Portincasa, P. A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes. World J. Gastroenterol., 2013, 19(20), 3007-3017.
[http://dx.doi.org/10.3748/wjg.v19.i20.3007] [PMID: 23716980]
[38]
Morazzoni, P.; Montalbetti, A.; Malandrino, S.; Pifferi, G. Comparative pharmacokinetics of silipide and silymarin in rats. Eur. J. Drug Metab. Pharmacokinet., 1993, 18(3), 289-297.
[http://dx.doi.org/10.1007/BF03188811] [PMID: 8149949]
[39]
Conti, M.; Malandrino, S.; Magistretti, M.J. Protective activity of silipide on liver damage in rodents. Jpn. J. Pharmacol., 1992, 60(4), 315-321.
[http://dx.doi.org/10.1254/jjp.60.315] [PMID: 1287266]
[40]
Maiti, K.; Mukherjee, K.; Gantait, A.; Ahamed, H.N.; Saha, B.P.; Mukherjee, P.K. Enhanced therapeutic benefit of quercetinphospholipid complex in carbon tetrachloride-induced acute liver injury in rats: A comparative study. Iran. J. Pharmacol. Therapeut., 2005, 4, 84-90.
[41]
Cuomo, J.; Appendino, G.; Dern, A.S.; Schneider, E.; McKinnon, T.P.; Brown, M.J.; Togni, S.; Dixon, B.M. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J. Nat. Prod., 2011, 74(4), 664-669.
[http://dx.doi.org/10.1021/np1007262] [PMID: 21413691]
[42]
Bashang, H.; Tamma, S. The use of curcumin as an effective adjuvant to cancer therapy: A short review. Biotechnol. Appl. Biochem., 2020, 67(2), 171-179.
[http://dx.doi.org/10.1002/bab.1836] [PMID: 31608504]
[43]
Shabaninejad, Z.; Pourhanifeh, M.H.; Movahedpour, A.; Mottaghi, R.; Nickdasti, A.; Mortezapour, E.; Shafiee, A.; Hajighadimi, S.; Moradizarmehri, S.; Sadeghian, M.; Mousavi, S.M.; Mirzaei, H. Therapeutic potentials of curcumin in the treatment of glioblstoma. Eur. J. Med. Chem., 2020, 188112040
[http://dx.doi.org/10.1016/j.ejmech.2020.112040] [PMID: 31927312]
[44]
Lee, J.E.; Yoon, S.S.; Moon, E.Y. Curcumin-induced autophagy augments its antitumor effect against A172 human glioblastoma cells. Biomol. Ther. (Seoul), 2019, 27(5), 484-491.
[http://dx.doi.org/10.4062/biomolther.2019.107] [PMID: 31405268]
[45]
Liu, W.; Huang, M.; Zou, Q.; Lin, W. Curcumin suppresses gastric cancer biological activity by regulation of miRNA-21: An in vitro study. Int. J. Clin. Exp. Pathol., 2018, 11(12), 5820-5829.
[PMID: 31949668]
[46]
Chen, L.; Zhan, C.Z.; Wang, T.; You, H.; Yao, R. Curcumin inhibits the proliferation, migration, invasion, and apoptosis of diffuse large B-cell lymphoma cell line by regulating MiR-21/VHL axis. Yonsei Med. J., 2020, 61(1), 20-29.
[http://dx.doi.org/10.3349/ymj.2020.61.1.20] [PMID: 31887796]
[47]
Halder, R.C.; Almasi, A.; Sagong, B.; Leung, J.; Jewett, A.; Fiala, M. Curcuminoids and ω-3 fatty acids with anti-oxidants potentiate cytotoxicity of natural killer cells against pancreatic ductal adenocarcinoma cells and inhibit interferon γ production. Front. Physiol., 2015, 6, 129.
[http://dx.doi.org/10.3389/fphys.2015.00129] [PMID: 26052286]
[48]
Marquardt, J.U.; Gomez-Quiroz, L.; Arreguin Camacho, L.O.; Pinna, F.; Lee, Y.H.; Kitade, M.; Domínguez, M.P.; Castven, D.; Breuhahn, K.; Conner, E.A.; Galle, P.R.; Andersen, J.B.; Factor, V.M.; Thorgeirsson, S.S. Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer. J. Hepatol., 2015, 63(3), 661-669.
[http://dx.doi.org/10.1016/j.jhep.2015.04.018] [PMID: 25937435]
[49]
Calibasi-Kocal, G.; Pakdemirli, A.; Bayrak, S.; Ozupek, N.M.; Sever, T.; Basbinar, Y.; Ellidokuz, H.; Yigitbasi, T. Curcumin effects on cell proliferation, angiogenesis and metastasis in colorectal cancer, Journal of B.U.ON. Off. J. Balkan Union Oncol., 2019, 24, 1487-1482.
[50]
Gökçe Kütük, S.; Gökçe, G.; Kütük, M.; Gürses Cila, H.E.; Nazıroğlu, M. Curcumin enhances cisplatin-induced human laryngeal squamous cancer cell death through activation of TRPM2 channel and mitochondrial oxidative stress. Sci. Rep., 2019, 9(1), 17784.
[http://dx.doi.org/10.1038/s41598-019-54284-x] [PMID: 31780732]
[51]
Falke, J.; Parkkinen, J.; Vaahtera, L.; Hulsbergen-van de Kaa, C.A.; Oosterwijk, E.; Witjes, J.A. Curcumin as treatment for bladder cancer: A preclinical study of cyclodextrin-curcumin complex and BCG as intravesical treatment in an orthotopic bladder cancer rat model. BioMed Res. Int., 2018, 20189634902
[http://dx.doi.org/10.1155/2018/9634902] [PMID: 29984253]
[52]
Wang, J.; Wang, Z.; Wang, H.; Zhao, J.; Zhang, Z. Curcumin induces apoptosis in EJ bladder cancer cells via modulating c-myc and PI3K/Akt signaling Pathway. World J. Oncol., 2011, 2(3), 113-122.
[http://dx.doi.org/10.4021/wjon335w] [PMID: 29147235]
[53]
Brouwer-Visser, J.; Huang, G.S. IGF2 signaling and regulation in cancer. Cytokine Growth Factor Rev., 2015, 26(3), 371-377.
[http://dx.doi.org/10.1016/j.cytogfr.2015.01.002] [PMID: 25704323]
[54]
Dong, Y.; Li, J.; Han, F.; Chen, H.; Zhao, X.; Qin, Q.; Shi, R.; Liu, J. High IGF2 expression is associated with poor clinical outcome in human ovarian cancer. Oncol. Rep., 2015, 34(2), 936-942.
[http://dx.doi.org/10.3892/or.2015.4048] [PMID: 26063585]
[55]
Weischenfeldt, J.; Dubash, T.; Drainas, A.P.; Mardin, B.R.; Chen, Y.; Stütz, A.M.; Waszak, S.M.; Bosco, G.; Halvorsen, A.R.; Raeder, B.; Efthymiopoulos, T.; Erkek, S.; Siegl, C.; Brenner, H.; Brustugun, O.T.; Dieter, S.M.; Northcott, P.A.; Petersen, I.; Pfister, S.M.; Schneider, M.; Solberg, S.K.; Thunissen, E.; Weichert, W.; Zichner, T.; Thomas, R.; Peifer, M.; Helland, A.; Ball, C.R.; Jechlinger, M.; Sotillo, R.; Glimm, H.; Korbel, J.O. Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nat. Genet., 2017, 49(1), 65-74.
[http://dx.doi.org/10.1038/ng.3722] [PMID: 27869826]
[56]
Nordin, M.; Bergman, D.; Halje, M.; Engström, W.; Ward, A. Epigenetic regulation of the Igf2/H19 gene cluster. Cell Prolif., 2014, 47(3), 189-199.
[http://dx.doi.org/10.1111/cpr.12106] [PMID: 24738971]
[57]
Hamamura, K.; Zhang, P.; Yokota, H. IGF2-driven PI3 kinase and TGFbeta signaling pathways in chondrogenesis. Cell Biol. Int., 2008, 32(10), 1238-1246.
[http://dx.doi.org/10.1016/j.cellbi.2008.07.007] [PMID: 18675921]
[58]
Leick, M.B.; Shoff, C.J.; Wang, E.C.; Congress, J.L.; Gallicano, G.I. Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer. Am. J. Stem Cells, 2011, 1(1), 59-74.
[PMID: 23671798]
[59]
Tian, B.; Zhao, Y.; Liang, T.; Ye, X.; Li, Z.; Yan, D.; Fu, Q.; Li, Y. Curcumin inhibits urothelial tumor development by suppressing IGF2 and IGF2-mediated PI3K/AKT/mTOR signaling pathway. J. Drug Target., 2017, 25(7), 626-636.
[http://dx.doi.org/10.1080/1061186X.2017.1306535] [PMID: 28286973]
[60]
Shi, J.; Wang, Y.; Jia, Z.; Gao, Y.; Zhao, C.; Yao, Y. Curcumin inhibits bladder cancer progression via regulation of β-catenin expression. Tumour Biol., 2017, 39(7)1010428317702548
[http://dx.doi.org/10.1177/1010428317702548] [PMID: 28705118]
[61]
Wang, D.; Kong, X.; Li, Y.; Qian, W.; Ma, J.; Wang, D.; Yu, D.; Zhong, C. Curcumin inhibits bladder cancer stem cells by suppressing Sonic Hedgehog pathway. Biochem. Biophys. Res. Commun., 2017, 493(1), 521-527.
[http://dx.doi.org/10.1016/j.bbrc.2017.08.158] [PMID: 28870814]
[62]
Zhang, L.; Yang, G.; Zhang, R.; Dong, L.; Chen, H.; Bo, J.; Xue, W.; Huang, Y. Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells. Int. J. Oncol., 2018, 53(2), 515-526.
[http://dx.doi.org/10.3892/ijo.2018.4423] [PMID: 29901071]
[63]
Mani, J.; Fleger, J.; Rutz, J.; Maxeiner, S.; Bernd, A.; Kippenberger, S.; Zöller, N.; Chun, F.K.; Relja, B.; Juengel, E.; Blaheta, R.A. Curcumin combined with exposure to visible light blocks bladder cancer cell adhesion and migration by an integrin dependent mechanism. Eur. Rev. Med. Pharmacol. Sci., 2019, 23(23), 10564-10574.
[PMID: 31841214]
[64]
Cho, C.J.; Yang, C.W.; Wu, C.L.; Ho, J.Y.; Yu, C.P.; Wu, S.T.; Yu, D.S. The modulation study of multiple drug resistance in bladder cancer by curcumin and resveratrol. Oncol. Lett., 2019, 18(6), 6869-6876.
[http://dx.doi.org/10.3892/ol.2019.11023] [PMID: 31807190]
[65]
Afsharmoghadam, N.; Haghighatian, Z.; Mazdak, H.; Mirkheshti, N.; Mehrabi Koushki, R.; Alavi, S.A. Concentration-dependent effects of curcumin on 5-fluorouracil efficacy in bladder cancer cells. Asian Pac. J. Cancer Prev., 2017, 18(12), 3225-3230.
[PMID: 29281876]
[66]
Shi, J.; Zhang, X.; Shi, T.; Li, H. Antitumor effects of curcumin in human bladder cancer in vitro. Oncol. Lett., 2017, 14(1), 1157-1161.
[http://dx.doi.org/10.3892/ol.2017.6205] [PMID: 28693289]
[67]
Pan, Z.J.; Deng, N.; Zou, Z.H.; Chen, G.X. The effect of curcumin on bladder tumor in rat model. Eur. Rev. Med. Pharmacol. Sci., 2017, 21(4), 884-889.
[PMID: 28272691]
[68]
Sun, X.; Deng, Q.F.; Liang, Z.F.; Zhang, Z.Q.; Zhao, L.; Geng, H.; Xie, D.D.; Wang, Y.; Yu, D.X.; Zhong, C.Y. Curcumin reverses benzidine-induced cell proliferation by suppressing ERK1/2 pathway in human bladder cancer T24 cells, Experimental and toxicologic pathology. Off. J. Gesellschaft Toxikol. Pathol., 2016, 68, 215-222.
[69]
Liang, Z.; Xie, W.; Wu, R.; Geng, H.; Zhao, L.; Xie, C.; Li, X.; Zhu, M.; Zhu, W.; Zhu, J.; Huang, C.; Ma, X.; Wu, J.; Geng, S.; Zhong, C.; Han, H. Inhibition of tobacco smoke-induced bladder MAPK activation and epithelial-mesenchymal transition in mice by curcumin. Int. J. Clin. Exp. Pathol., 2015, 8(5), 4503-4513.
[PMID: 26191140]
[70]
Zhang, S.N.; Yong, Q.; Wu, X.L.; Liu, X.P. Synergism inhibition of curcumin combined with cisplatin on T24 bladder carcinoma cells and its related mechanism. Zhong Yao Cai, 2014, 37(11), 2043-2046.
[PMID: 26027129]
[71]
Gao, Y.; Shi, Q.; Xu, S.; Du, C.; Liang, L.; Wu, K.; Wang, K.; Wang, X.; Chang, L.S.; He, D.; Guo, P. Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells. Int. J. Mol. Sci., 2014, 15(9), 15173-15187.
[http://dx.doi.org/10.3390/ijms150915173] [PMID: 25170806]
[72]
Pichu, S.; Krishnamoorthy, S.; Shishkov, A.; Zhang, B.; McCue, P.; Ponnappa, B.C. Knockdown of Ki-67 by dicer-substrate small interfering RNA sensitizes bladder cancer cells to curcumin-induced tumor inhibition. PLoS One, 2012, 7(11)e48567
[http://dx.doi.org/10.1371/journal.pone.0048567] [PMID: 23152782]
[73]
Wu, S.Y.; Lee, Y.R.; Huang, C.C.; Li, Y.Z.; Chang, Y.S.; Yang, C.Y.; Wu, J.D.; Liu, Y.W. Curcumin-induced heme oxygenase-1 expression plays a negative role for its anti-cancer effect in bladder cancers, Food and chemical toxicology. Int. J. Publ. Brit. Indust. Biol. Res. Assoc., 2012, 50, 3530-3536.
[74]
Liu, H.S.; Ke, C.S.; Cheng, H.C.; Huang, C.Y.; Su, C.L. Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A. Mol. Pharmacol., 2011, 80(4), 638-646.
[http://dx.doi.org/10.1124/mol.111.072512] [PMID: 21757545]
[75]
Chadalapaka, G.; Jutooru, I.; Burghardt, R.; Safe, S. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol. Cancer Res., 2010, 8(5), 739-750.
[http://dx.doi.org/10.1158/1541-7786.MCR-09-0493] [PMID: 20407012]
[76]
Leite, K.R.; Chade, D.C.; Sanudo, A.; Sakiyama, B.Y.; Batocchio, G.; Srougi, M. Effects of curcumin in an orthotopic murine bladder tumor model. Int. Braz J Urol, 2009, 35, 599-606.
[77]
Chadalapaka, G.; Jutooru, I.; Chintharlapalli, S.; Papineni, S.; Smith, R., III; Li, X.; Safe, S. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res., 2008, 68(13), 5345-5354.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-6805] [PMID: 18593936]
[78]
Tian, B.; Wang, Z.; Zhao, Y.; Wang, D.; Li, Y.; Ma, L.; Li, X.; Li, J.; Xiao, N.; Tian, J.; Rodriguez, R. Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett., 2008, 264(2), 299-308.
[http://dx.doi.org/10.1016/j.canlet.2008.01.041] [PMID: 18342436]
[79]
Kamat, A.M.; Sethi, G.; Aggarwal, B.B. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol. Cancer Ther., 2007, 6(3), 1022-1030.
[http://dx.doi.org/10.1158/1535-7163.MCT-06-0545] [PMID: 17363495]
[80]
Park, C.; Kim, G.Y.; Kim, G.D.; Choi, B.T.; Park, Y.M.; Choi, Y.H. Induction of G2/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24 cells. Oncol. Rep., 2006, 15(5), 1225-1231.
[http://dx.doi.org/10.3892/or.15.5.1225] [PMID: 16596191]
[81]
Sun, M.; Yang, Y.; Li, H.; Su, B.; Lu, Y.; Wei, Q.; Fan, T. The effect of curcumin on bladder cancer cell line EJ in vitro. Zhong Yao Cai, 2004, 27(11), 848-850.
[PMID: 15810596]
[82]
Sindhwani, P.; Hampton, J.A.; Baig, M.M.; Keck, R.; Selman, S.H. Curcumin prevents intravesical tumor implantation of the MBT-2 tumor cell line in C3H mice. J. Urol., 2001, 166(4), 1498-1501.
[http://dx.doi.org/10.1016/S0022-5347(05)65819-3] [PMID: 11547120]
[83]
Roos, F.; Binder, K.; Rutz, J.; Maxeiner, S.; Bernd, A.; Kippenberger, S.; Zoller, N.; Chun, F.K.; Juengel, E.; Blaheta, R.A. The antitumor effect of curcumin in urothelial cancer cells is enhanced by light exposure in vitro. Evid. Based Complement. Alternat. Med., 2019, 20196374940
[84]
Xu, R.; Li, H.; Wu, S.; Qu, J.; Yuan, H.; Zhou, Y.; Lu, Q. MicroRNA-1246 regulates the radio-sensitizing effect of curcumin in bladder cancer cells via activating P53. Int. Urol. Nephrol., 2019, 51(10), 1771-1779.
[http://dx.doi.org/10.1007/s11255-019-02210-5] [PMID: 31236854]
[85]
Saini, S.; Arora, S.; Majid, S.; Shahryari, V.; Chen, Y.; Deng, G.; Yamamura, S.; Ueno, K.; Dahiya, R. Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev. Res. (Phila.), 2011, 4(10), 1698-1709.
[http://dx.doi.org/10.1158/1940-6207.CAPR-11-0267] [PMID: 21836020]
[86]
Wang, K.; Tan, S.L.; Lu, Q.; Xu, R.; Cao, J.; Wu, S.Q.; Wang, Y.H.; Zhao, X.K.; Zhong, Z.H. Curcumin suppresses microRNA-7641-mediated regulation of p16 expression in bladder cancer. Am. J. Chin. Med., 2018, 46(6), 1357-1368.
[http://dx.doi.org/10.1142/S0192415X18500714] [PMID: 30149755]
[87]
Shao, Y.; Zhu, W.; Da, J.; Xu, M.; Wang, Y.; Zhou, J.; Wang, Z. Bisdemethoxycurcumin in combination with α-PD-L1 antibody boosts immune response against bladder cancer. OncoTargets Ther., 2017, 10, 2675-2683.
[http://dx.doi.org/10.2147/OTT.S130653] [PMID: 28579805]
[88]
Kang, M.; Ho, J.N.; Kook, H.R.; Lee, S.; Oh, J.J.; Hong, S.K.; Lee, S.E.; Byun, S.S. Theracurmin® efficiently inhibits the growth of human prostate and bladder cancer cells via induction of apoptotic cell death and cell cycle arrest. Oncol. Rep., 2016, 35(3), 1463-1472.
[http://dx.doi.org/10.3892/or.2015.4537] [PMID: 26718024]
[89]
Tong, Q.S.; Zheng, L.D.; Lu, P.; Jiang, F.C.; Chen, F.M.; Zeng, F.Q.; Wang, L.; Dong, J.H. Apoptosis-inducing effects of curcumin derivatives in human bladder cancer cells. Anticancer Drugs, 2006, 17(3), 279-287.
[http://dx.doi.org/10.1097/00001813-200603000-00006] [PMID: 16520656]
[90]
Ramezani, M.; Hatamipour, M.; Sahebkar, A. Promising anti-tumor properties of bisdemethoxycurcumin: A naturally occurring curcumin analogue. J. Cell. Physiol., 2018, 233(2), 880-887.
[http://dx.doi.org/10.1002/jcp.25795] [PMID: 28075008]
[91]
Gordon, O.N.; Luis, P.B.; Ashley, R.E.; Osheroff, N.; Schneider, C. Oxidative transformation of demethoxy- and bisdemethoxycurcumin: Products, mechanism of formation, and poisoning of human topoisomerase IIα. Chem. Res. Toxicol., 2015, 28(5), 989-996.
[http://dx.doi.org/10.1021/acs.chemrestox.5b00009] [PMID: 25806475]
[92]
Sandur, S.K.; Pandey, M.K.; Sung, B.; Ahn, K.S.; Murakami, A.; Sethi, G.; Limtrakul, P.; Badmaev, V.; Aggarwal, B.B. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis, 2007, 28(8), 1765-1773.
[http://dx.doi.org/10.1093/carcin/bgm123] [PMID: 17522064]
[93]
Fiala, M.; Liu, P.T.; Espinosa-Jeffrey, A.; Rosenthal, M.J.; Bernard, G.; Ringman, J.M.; Sayre, J.; Zhang, L.; Zaghi, J.; Dejbakhsh, S.; Chiang, B.; Hui, J.; Mahanian, M.; Baghaee, A.; Hong, P.; Cashman, J. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer’s disease patients are improved by bisdemethoxycurcumin. Proc. Natl. Acad. Sci. USA, 2007, 104(31), 12849-12854.
[http://dx.doi.org/10.1073/pnas.0701267104] [PMID: 17652175]
[94]
Sivabalan, S.; Anuradha, C. A comparative study on the antioxidant and glucose-lowering effects of curcumin and bisdemethoxycurcumin analog through in vitro assays. Int. J. Pharmacol., 2010, 6, 664-669.
[http://dx.doi.org/10.3923/ijp.2010.664.669]
[95]
Lin, T.H.; Izumi, K.; Lee, S.O.; Lin, W.J.; Yeh, S.; Chang, C. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis., 2013, 4e764
[http://dx.doi.org/10.1038/cddis.2013.270] [PMID: 23928703]
[96]
Hsu, J.W.; Hsu, I.; Xu, D.; Miyamoto, H.; Liang, L.; Wu, X.R.; Shyr, C.R.; Chang, C. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am. J. Pathol., 2013, 182(5), 1811-1820.
[http://dx.doi.org/10.1016/j.ajpath.2013.01.018] [PMID: 23499463]
[97]
Yadav, B.; Taurin, S.; Rosengren, R.J.; Schumacher, M.; Diederich, M.; Somers-Edgar, T.J.; Larsen, L. Synthesis and cytotoxic potential of heterocyclic cyclohexanone analogues of curcumin. Bioorg. Med. Chem., 2010, 18(18), 6701-6707.
[http://dx.doi.org/10.1016/j.bmc.2010.07.063] [PMID: 20728364]
[98]
Prasad, S.; Tyagi, A.K.; Aggarwal, B.B. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: The golden pigment from golden spice, Cancer research and treatment. Off. J. Korean Cancer Assoc., 2014, 46, 2-18.
[99]
Samaddar, S.; Mazur, J.; Boehm, D.; Thompson, D.H. Development and in vitro characterization of bladder tumor cell targeted lipid-coated polyplex for dual delivery of plasmids and small molecules. Int. J. Nanomedicine, 2019, 14, 9547-9561.
[http://dx.doi.org/10.2147/IJN.S225172] [PMID: 31824150]

Rights & Permissions Print Cite
Article Metrics
15
1
© 2024 Bentham Science Publishers | Privacy Policy